Realgar induces apoptosis in the chronic lymphocytic leukemia cell line MEC-1

Molecular Medicine Reports

Volumn 8, Issue 6, 2013, Pages 1866-1870

  Liu, Xinyu ^a   Li, Xianglu ^a   Wang, Ling ^a   Lv, Xiao ^a   Chen, Na ^a   Li, Peipei ^a   Lu, Kang ^a   Wang, Xin ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Apoptosis; Chronic lymphocytic leukemia; Realgar

Indexed keywords

ARSENIC DISULFIDE; CYCLIN DEPENDENT KINASE INHIBITOR 1A; MESSENGER RNA; MYC PROTEIN; ORGANOARSENIC DERIVATIVE; PROTEIN BAX; PROTEIN BCL X; SULFIDE;

APOPTOSIS; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; DOWN REGULATION; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; HUMAN; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

APOPTOSIS; ARSENICALS; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOWN-REGULATION; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PROTO-ONCOGENE PROTEINS C-MYC; RNA, MESSENGER; SULFIDES; TRANSCRIPTION, GENETIC;

EID: 84893795264     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2013.1731     Document Type: Article

References (28)

1. Man S, Gao W, Wei C and Liu C: Anticancer drugs from traditional toxic Chinese medicines. Phytother Res 26: 1449-1465, 2012.
2. Soignet SL, Maslak P, Wang ZG, et al: Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 339: 1341-1348, 1998.
3. Lu J, Chew EH and Holmgren A: Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide. Proc Natl Acad Sci USA 104: 12288-12293, 2007.
4. Hu J, Liu YF, Wu CF, et al: Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA 106: 3342-3347, 2009.
5. Kim J, Lee JJ, Kim J, Gardner D and Beachy PA: Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector. Proc Natl Acad Sci USA 107: 13432-13437, 2010.
6. Zhang XW, Yan XJ, Zhou ZR, et al: Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science 328: 240-243, 2010.
7. Mahieux R, Pise-Masison C, Gessain A, et al: Arsenic trioxide induces apoptosis in human T-cell leukemia virus type 1-and type 2-infected cells by a caspase-3-dependent mechanism involving Bcl-2 cleavage. Blood 98: 3762-3769, 2001.
8. Bae-Jump VL, Zhou C, Boggess JF and Gehrig PA: Arsenic trioxide (As2O3) inhibits expression of estrogen receptor-alpha through regulation of the mitogen-activated protein kinase (MAPK) pathway in endometrial cancer cells. Reprod Sci 15: 1011-1017, 2008.
9. Kang YH and Lee SJ: The role of p38 MAPK and JNK in Arsenic trioxide-induced mitochondrial cell death in human cervical cancer cells. J Cell Physiol 217: 23-33, 2008.
10. Ahn RW, Chen F, Chen H, et al: A novel nanoparticulate formulation of arsenic trioxide with enhanced therapeutic efficacy in a murine model of breast cancer. Clin Cancer Res 16: 3607-3617, 2010.
11. Raju GP: Arsenic: a potentially useful poison for Hedgehog-driven cancers. J Clin Invest 121: 14-16, 2011.
12. Hu XM, Liu F and Ma R: Application and assessment of Chinese arsenic drugs in treating malignant hematopathy in China. Chin J Integr Med 16: 368-377, 2010.
13. Xiang Y, Wang XB, Sun SJ, et al: Compound huangdai tablet as induction therapy for 193 patients with acute promyelocytic leukemia. Zhonghua Xue Ye Xue Za Zhi 30: 440-442, 2009 (In Chinese).
14. Li JE, Wu WL, Wang ZY and Sun GL: Apoptotic effect of As2S2 on K562 cells and its mechanism. Acta Pharmacol Sin 23: 991-996, 2002.
15. Mao JH, Sun XY, Liu JX, et al: As4S4 targets RING-type E3 ligase c-CBL to induce degradation of BCR-ABL in chronic myelogenous leukemia. Proc Natl Acad Sci USA 107: 21683-21688, 2010.
16. Bairey O, Vanichkin A and Shpilberg O: Arsenic-trioxide-induced apoptosis of chronic lymphocytic leukemia cells. Int J Lab Hematol 32 (1 Pt 1): e77-e85, 2010.
17. Redondo-Muñoz J, Escobar-Díaz E, Hernández Del Cerro M, et al: Induction of B-chronic lymphocytic leukemia cell apoptosis by arsenic trioxide involves suppression of the phosphoinositide 3-kinase/Akt survival pathway via c-jun-NH2 terminal kinase activation and PTEN upregulation. Clin Cancer Res 16: 4382-4391, 2010.
18. Yin T, Wu YL, Sun HP, et al: Combined effects of As4S4 and imatinib on chronic myeloid leukemia cells and BCR-ABL oncoprotein. Blood 104: 4219-4225, 2004.
19. Zhao QH, Zhang Y, Liu Y, et al: Anticancer effect of realgar nanoparticles on mouse melanoma skin cancer in vivo via transdermal drug delivery. Med Oncol 27: 203-212, 2010.
20. An YL, Nie F, Wang ZY and Zhang DS: Preparation and characterization of realgar nanoparticles and their inhibitory effect on rat glioma cells. Int J Nanomedicine 6: 3187-3194, 2011.
21. Cheng YX, Liu R, Wang Q, et al: Realgar-induced apoptosis of cervical cancer cell line Siha via cytochrome c release and caspase-3 and caspase-9 activation. Chin J Integr Med 18: 359-365, 2012.
22. Ye HQ, Gan L, Yang XL and Xu HB: Membrane-associated cytotoxicity induced by realgar in promyelocytic leukemia HL-60 cells. J Ethnopharmacol 103: 366-371, 2006.
23. Wang XB, Gao HY, Hou BL, Huang J, Xi RG and Wu LJ: Nanoparticle realgar powders induce apoptosis in U937 cells through caspase MAPK and mitochondrial pathways. Arch Pharm Res 30: 653-658, 2007.
24. Xi RG, Huang J, Li D, Wang XB and Wu LJ: Roles of PI3-K/Akt pathways in nanoparticle realgar powders-induced apoptosis in U937 cells. Acta Pharmacol Sin 29: 355-363, 2008.
25. Klein U and Dalla-Favera R: New insights into the pathogenesis of chronic lymphocytic leukemia. Semin Cancer Biol 20: 377-383, 2010.
26. Damle RN, Calissano C and Chiorazzi N: Chronic lymphocytic leukaemia: a disease of activated monoclonal B cells. Best Pract Res Clin Haematol 23: 33-45, 2010.
27. Stacchini A, Aragno M, Vallario A, et al: MEC1 and MEC2: two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphocytoid transformation. Leuk Res 23: 127-136, 1999.
28. Buggins AG and Pepper CJ: The role of Bcl-2 family proteins in chronic lymphocytic leukaemia. Leuk Res 34: 837-842, 2010.